205 related articles for article (PubMed ID: 21114864)
1. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
[TBL] [Abstract][Full Text] [Related]
2. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
Lu Y; Yao HP; Wang MH
J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
[TBL] [Abstract][Full Text] [Related]
4. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
Zhang K; Zhou YQ; Yao HP; Wang MH
Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
[TBL] [Abstract][Full Text] [Related]
5. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
6. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines.
Chen YQ; Zhou YQ; Angeloni D; Kurtz AL; Qiang XZ; Wang MH
Exp Cell Res; 2000 Nov; 261(1):229-38. PubMed ID: 11082293
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
Xu XM; Zhou YQ; Wang MH
J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
[TBL] [Abstract][Full Text] [Related]
10. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
[TBL] [Abstract][Full Text] [Related]
11. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.
Zhang K; Yao HP; Wang MH
Carcinogenesis; 2008 Mar; 29(3):552-9. PubMed ID: 18204077
[TBL] [Abstract][Full Text] [Related]
12. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
13. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
14. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.
Wei X; Hao L; Ni S; Liu Q; Xu J; Correll PH
J Biol Chem; 2005 Dec; 280(48):40241-51. PubMed ID: 16166096
[TBL] [Abstract][Full Text] [Related]
15. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.
Bardella C; Costa B; Maggiora P; Patane' S; Olivero M; Ranzani GN; De Bortoli M; Comoglio PM; Di Renzo MF
Cancer Res; 2004 Aug; 64(15):5154-61. PubMed ID: 15289319
[TBL] [Abstract][Full Text] [Related]
16. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
17. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
[TBL] [Abstract][Full Text] [Related]
18. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
20. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
Collesi C; Santoro MM; Gaudino G; Comoglio PM
Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
